Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Improving speech in Parkinson's patients with deep brain stimulation

Official title: REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis

Run by Insel Gruppe AG, University Hospital Bern · NCT05182892 · Data updated 2026-11-12

This study is testing if deep brain stimulation can improve speech quality in people with Parkinson's disease while also looking at how medication affects their speech.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment45 (estimated)
SponsorInsel Gruppe AG, University Hospital Bern
Academic / other
Locations2 sites (Prague and 1 other locations)
StatusRecruiting
StartedDecember 13, 2021
Main results expectedNovember 30, 2025
Study endsFebruary 28, 2026
Registry record updatedApril 9, 2025
Trial IDNCT05182892 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include individuals with idiopathic Parkinson's disease who have undergone bilateral deep brain stimulation and experience speech difficulties related to the treatment.

Probably not a fit

Patients whose speech disorders are caused by conditions other than Parkinson's disease or deep brain stimulation, such as stroke or myasthenia, may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance speech quality in patients with Parkinson's disease who experience speech disorders due to deep brain stimulation (DBS) of the subthalamic nucleus. By utilizing automated acoustic analysis, the researchers will identify specific speech variables that can help differentiate between speech improvements and side effects caused by DBS. The study will assess patients in both medicated and unmedicated states to gather comprehensive data on their speech patterns. The ultimate goal is to reduce the incidence of dysarthria associated with DBS while improving overall communication abilities.

Why it matters

Potential benefit: If successful, this approach could significantly improve the quality of life for Parkinson's patients by enhancing their speech capabilities.

How similar studies have gone: While there have been studies on speech disorders in Parkinson's disease, the specific use of automated acoustic analysis in conjunction with DBS is a novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Idiopathic Parkinson-Syndrome according to the Movement Disorders Society Criteria
* Treatment with bilateral deep brain stimulation in the subthalamic nucleus (for parts 1, 2 and 3)
* Time since DBS-STN operation ≥ 3 month (for parts 1, 2 and 3)
* Able to give informed consent as documented by signature
* Fluent in Swiss-German or German
* STN-DBS-induced dysarthria. In an operational definition, all PD-patients who reported -worsening of speech time-locked to STN-DBS implantation or patients with dysarthria on chronic stimulation improving with reduction of stimulation amplitudes in the context of postoperative routine follow up will be defined as having STN-DBS-induced dysarthria

Exclusion Criteria:

* Dysarthria caused in addition by a condition other than PD or DBS (e.g. stroke, myasthenia)
* Clinical diagnosis of aphasia
* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders and dementia. A Montreal Cognitive Assesment (MoCa) will be performed and patients with ≤ 20 of 30 points will be excluded
* Change of parkinsonian medication in the last four weeks prior to inclusion in part 1 and 3
* Change of STN-DBS parameters in the last four weeks prior to inclusion (for parts 1 and 3)
* Depression with acute suicidal ideation
* Pregnant women

Where it's running

  • University Hospital Inselspital, Berne
    Bern, Switzerland
    Recruiting
  • Czech Technical University Prague
    Prague, Czechia
    Active not recruiting

Study contacts

  • Principal investigator: Paul Krack, Prof. — Insel Gruppe AG, University Hospital Bern
  • Study coordinator: Paul Krack, Prof.
  • Email: paul.krack@insel.ch
  • Phone: 31 632 21 68

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.